RESEARCH TRIANGLE PARK, NC--(Marketwire - August 15, 2008) - The finding comes out of a new
study released by market intelligence firm Cutting Edge Information.
According to Cutting Edge Information's research, total oncology sales will
grow by 56% between 2007 and 2012. 2007 sales amounted to approximately
$18 billion.
The new report, "The Oncology Market Forecast to 2013," is a comprehensive
study of more than 135 oncology drugs. The study takes a close look at the
market for five major oncology indications, including colorectal, leukemia,
lung, prostate and breast cancer. It also includes detailed forecasts for
each drug, including forecasts for individual drug classes and top oncology
drug manufacturers
(
http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp).
The market outlook for breast cancer treatments is bright indeed. Roche's
and Genentech's blockbusters Avastin and Herceptin are currently undergoing
clinical testing for cancer treatment. Meanwhile, several developmental
drugs -- including Novartis' Gleevec -- are poised to take on the breast
cancer market within the next couple of years. Gleevec is in Phase 3
trials for advanced breast cancer, and is expected to be a boon for
Novartis on the order of several billion in annual sales.
"The market for breast cancer treatment is certainly on an upward
trajectory," said Eric Bolesh, lead author of the study. "Several
promising therapies are in the pipeline, and the options for treatment are
ever-expanding -- which is good news for the industry and for patients."
The 420+ page study examines 17 monoclonal antibodies and more than 120
other drugs, and provides the following market analysis:
-- Individual Drug Profiles - Drug profiles include information about
drugs' competitive, strategic and market growth positions.
-- Oncology Indication Market Outlook - Detailed outlooks for the breast,
colorectal, lung and prostate cancer and leukemia markets.
-- Company Profiles - Oncology breakdowns for companies that either have
established oncology franchises or exciting development pipelines for new
cancer compounds.
Contact Information: CONTACT INFORMATION:
Eric Bolesh
919-433-0209